• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

未诊断的静脉闭塞性疾病/窦状隙阻塞综合征(VOD/SOS)是急性白血病移植患者多器官衰竭的主要原因:来自 EBMT 急性白血病工作组的分析。

Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.

机构信息

Sorbonne University, Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, INSERM UMR 938, Paris, France.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

出版信息

Bone Marrow Transplant. 2021 Apr;56(4):917-927. doi: 10.1038/s41409-020-01135-3. Epub 2020 Nov 18.

DOI:10.1038/s41409-020-01135-3
PMID:33208915
Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of complications. Triggering event(s) of such complications vary significantly, but often a so-called "multi-organ failure" (MOF) is reported as the leading cause of death. The identification of the exact trigger of MOF is critical towards early and disease-specific intervention to improve outcome. We examined data from 202 alloHCT patients reported to have died of MOF from the EBMT registry aiming to determine their exact cause of death focusing on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) due to its life-threatening, often difficult to capture yet preventable nature. We identified a total of 70 patients (35%) for whom VOD/SOS could be considered as trigger for MOF and leading cause of death, among which 48 (69%) were previously undiagnosed. Multivariate analysis highlighted history of hepatic comorbidity or gentuzumab use and disease status beyond CR1 as the only significant factors predictive of VOD/SOS incidence (OR = 6.6; p = 0.001 and OR = 3.3; p = 0.004 respectively). VOD/SOS-related MOF was widely under-reported, accounting for 27% of deaths attributed to MOF of unknown origin without a previous VOD/SOS diagnosis. Our results suggest most missed cases developed late VOD/SOS beyond 21 days post-alloHCT, highlighting the importance of the newly revised EBMT criteria.

摘要

异基因造血细胞移植(alloHCT)是一种复杂的、可能致命的治疗方法,具有多种并发症。这些并发症的触发因素差异很大,但通常报告所谓的“多器官衰竭”(MOF)是导致死亡的主要原因。确定 MOF 的确切触发因素对于早期和针对特定疾病的干预以改善结果至关重要。我们检查了来自 EBMT 登记处的 202 名报告因 MOF 死亡的 alloHCT 患者的数据,旨在确定他们的确切死因,重点关注静脉阻塞性疾病/窦状阻塞综合征(VOD/SOS),因为它具有威胁生命、常常难以捕捉但可预防的性质。我们共确定了 70 名(35%)患者,可将 VOD/SOS 视为 MOF 的触发因素和主要死因,其中 48 名(69%)患者之前未被诊断。多变量分析突出了肝合并症或 gentuzumab 使用史以及 CR1 以外的疾病状态是预测 VOD/SOS 发生率的唯一显著因素(OR=6.6;p=0.001 和 OR=3.3;p=0.004)。VOD/SOS 相关的 MOF 广泛漏报,占归因于 MOF 的未知来源的死亡的 27%,而没有之前的 VOD/SOS 诊断。我们的结果表明,大多数漏诊病例在 alloHCT 后 21 天以上发生晚期 VOD/SOS,突出了新修订的 EBMT 标准的重要性。

相似文献

1
Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.未诊断的静脉闭塞性疾病/窦状隙阻塞综合征(VOD/SOS)是急性白血病移植患者多器官衰竭的主要原因:来自 EBMT 急性白血病工作组的分析。
Bone Marrow Transplant. 2021 Apr;56(4):917-927. doi: 10.1038/s41409-020-01135-3. Epub 2020 Nov 18.
2
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.既往接受吉妥单抗奥佐米星治疗的急性髓系白血病成人患者在异基因造血细胞移植后发生肝静脉闭塞性疾病的风险并未增加:国际血液和骨髓移植研究中心分析
Biol Blood Marrow Transplant. 2020 May;26(5):884-892. doi: 10.1016/j.bbmt.2019.12.763. Epub 2019 Dec 28.
3
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH).未预处理单倍体造血干细胞移植后应用环磷酰胺治疗的窦状隙阻塞综合征/静脉闭塞病:西班牙造血干细胞移植和细胞治疗组(GETH)的一项研究。
Transplant Cell Ther. 2024 Sep;30(9):914.e1-914.e8. doi: 10.1016/j.jtct.2024.06.003. Epub 2024 Jun 7.
4
BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.BCSH/BSBMT 指南:造血干细胞移植后静脉闭塞病(窦状隙阻塞综合征)的诊断和治疗。
Br J Haematol. 2013 Nov;163(4):444-57. doi: 10.1111/bjh.12558. Epub 2013 Sep 17.
5
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.儿童自体或异基因造血干细胞移植后窦状隙阻塞综合征/静脉闭塞性疾病:意大利血液学-肿瘤学会-造血干细胞移植组的回顾性研究。
Biol Blood Marrow Transplant. 2019 Feb;25(2):313-320. doi: 10.1016/j.bbmt.2018.09.027. Epub 2018 Sep 26.
6
Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.骨髓移植临床试验网络 1202 研究:骨髓移植中肝静脉闭塞病/窦状隙阻塞综合征的预后生物标志物。
Transplant Cell Ther. 2023 Mar;29(3):166.e1-166.e10. doi: 10.1016/j.jtct.2022.11.024. Epub 2022 Nov 28.
7
A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study.一项多中心、多国、前瞻性、观察性登记研究,评估在造血细胞移植后诊断为静脉闭塞病/肝窦阻塞综合征的患者中使用地塞米松的疗效:一项 EBMT 研究。
Bone Marrow Transplant. 2021 Oct;56(10):2454-2463. doi: 10.1038/s41409-021-01265-2. Epub 2021 May 31.
8
Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.改良 EBMT 诊断和严重程度标准 2023 年在窦状隙阻塞综合征/静脉阻塞性疾病中的应用。
Bone Marrow Transplant. 2024 Apr;59(4):518-525. doi: 10.1038/s41409-024-02215-4. Epub 2024 Jan 29.
9
Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.在异基因造血细胞移植前接受吉妥珠单抗奥佐米星治疗的急性髓系白血病患儿的静脉闭塞性疾病风险。
Pediatr Blood Cancer. 2021 Aug;68(8):e29067. doi: 10.1002/pbc.29067. Epub 2021 Apr 19.
10
Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.造血干细胞移植后,在静脉闭塞性疾病/窦性阻塞综合征诊断后更早开始使用去纤苷可提高第100天的生存率。
Br J Haematol. 2017 Jul;178(1):112-118. doi: 10.1111/bjh.14727. Epub 2017 Apr 26.

引用本文的文献

1
Biomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome.基于生物标志物的快速节俭决策树用于预测静脉闭塞性疾病/窦性阻塞综合征
Blood Adv. 2024 Oct 22;8(20):5426-5429. doi: 10.1182/bloodadvances.2024013670.
2
Hepatic Veno-Occlusive Disease and Colorectal Cancer: Expect the Unexpected.肝静脉闭塞病与结直肠癌:意料之外之事需有所预期。
Life (Basel). 2024 Jul 4;14(7):845. doi: 10.3390/life14070845.
3
Systematic screening and focused evaluation for veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) following allogeneic stem cell transplant is associated with earlier diagnosis and prompt institution of defibrotide treatment.
对异基因干细胞移植后静脉闭塞性疾病/窦性阻塞综合征(VOD/SOS)进行系统筛查和重点评估,有助于早期诊断并及时开始使用去纤苷治疗。
Front Transplant. 2022 Nov 8;1:996003. doi: 10.3389/frtra.2022.996003. eCollection 2022.
4
Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill.造血细胞移植及其他细胞治疗后内皮损伤综合征中的遗传易感性:艰难前行。
Curr Issues Mol Biol. 2024 May 15;46(5):4787-4802. doi: 10.3390/cimb46050288.
5
Retrospective analysis of veno-occlusive disease/sinusoidal obstruction syndrome in paediatric patients undergoing hematopoietic cell transplantation -a multicentre study.造血干细胞移植患儿静脉闭塞性疾病/窦性阻塞综合征的回顾性分析——一项多中心研究
Lancet Reg Health Am. 2024 Apr 6;33:100728. doi: 10.1016/j.lana.2024.100728. eCollection 2024 May.
6
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.成人异基因造血干细胞移植受者静脉闭塞病/窦状隙阻塞综合征的当前发生率、严重程度和处理:EBMT 移植并发症工作组研究。
Bone Marrow Transplant. 2023 Nov;58(11):1209-1214. doi: 10.1038/s41409-023-02077-2. Epub 2023 Aug 12.
7
Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation.低血浆透明质酸水平可能排除造血干细胞移植后发生窦状隙阻塞综合征。
Dis Markers. 2023 Apr 17;2023:7589017. doi: 10.1155/2023/7589017. eCollection 2023.
8
Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation.造血细胞移植后窦状隙阻塞综合征风险生物标志物的前瞻性评估。
JCI Insight. 2023 May 22;8(10):e168221. doi: 10.1172/jci.insight.168221.
9
The Importance of New EBMT Criteria on the Diagnosis of Veno-Occlusive Liver Disease in Children.新的欧洲血液和骨髓移植学会(EBMT)标准对儿童肝静脉闭塞病诊断的重要性
J Clin Med. 2023 Jan 20;12(3):826. doi: 10.3390/jcm12030826.
10
Handheld Ultrasound or Conventional Ultrasound Devices in Patients Undergoing HCT: A Validation Study.接受造血干细胞移植患者使用手持式超声或传统超声设备的验证研究
J Clin Med. 2023 Jan 8;12(2):520. doi: 10.3390/jcm12020520.